KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
Background: T cells and natural killer (NK) cells are essential components of the immune system and are regulated by coinhibitory and costimulatory molecules in which the B7 family and CD28 family play significant roles. Previous immune checkpoint studies on B7/CD28 family members, such as PD-1, hav...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Journal of Advanced Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2090123222001679 |
| _version_ | 1797837763216670720 |
|---|---|
| author | Yang Li Chao Lv Yang Yu Baokang Wu Yizhou Zhang Qi Lang Zhiyun Liang Chongli Zhong Yu Shi Shukun Han Feng Xu Yu Tian |
| author_facet | Yang Li Chao Lv Yang Yu Baokang Wu Yizhou Zhang Qi Lang Zhiyun Liang Chongli Zhong Yu Shi Shukun Han Feng Xu Yu Tian |
| author_sort | Yang Li |
| collection | DOAJ |
| description | Background: T cells and natural killer (NK) cells are essential components of the immune system and are regulated by coinhibitory and costimulatory molecules in which the B7 family and CD28 family play significant roles. Previous immune checkpoint studies on B7/CD28 family members, such as PD-1, have led to remarkable success in cancer immunotherapy. However, there is still a need to find new immune checkpoint molecules. Recent studies have demonstrated that HHLA2 exerts inhibitory and stimulatory functions on the immune system by binding to different receptors on different sites. However, the pathways between HHLA2 and its two receptors on T cells and NK cells remain controversial. Aim of Review: Here, we reviewed recent studies about HHLA2 ligand interactions with KIR3DL3 and TMIGD2. We focused on elucidating the pathways between KIR3DL3/TMIGD2 and HHLA2 as well as their function in tumour progression. We also addressed the relationship between HHLA2 expression and the clinical prognosis of cancer patients. Key Scientific Concepts of Review: KIR3DL3/TMIGD2-HHLA2 may represent novel pathways within the tumour microenvironment and serve as crucial immune checkpoints for developing novel therapeutic drugs against human cancer. |
| first_indexed | 2024-04-09T15:29:54Z |
| format | Article |
| id | doaj.art-3356e7b45740472096364e603ab0ba04 |
| institution | Directory Open Access Journal |
| issn | 2090-1232 |
| language | English |
| last_indexed | 2024-04-09T15:29:54Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Advanced Research |
| spelling | doaj.art-3356e7b45740472096364e603ab0ba042023-04-28T08:55:19ZengElsevierJournal of Advanced Research2090-12322023-05-0147137150KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapyYang Li0Chao Lv1Yang Yu2Baokang Wu3Yizhou Zhang4Qi Lang5Zhiyun Liang6Chongli Zhong7Yu Shi8Shukun Han9Feng Xu10Yu Tian11Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaThe First Clinical College of China Medical University, Shenyang 110001, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, ChinaDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China; Corresponding author.Background: T cells and natural killer (NK) cells are essential components of the immune system and are regulated by coinhibitory and costimulatory molecules in which the B7 family and CD28 family play significant roles. Previous immune checkpoint studies on B7/CD28 family members, such as PD-1, have led to remarkable success in cancer immunotherapy. However, there is still a need to find new immune checkpoint molecules. Recent studies have demonstrated that HHLA2 exerts inhibitory and stimulatory functions on the immune system by binding to different receptors on different sites. However, the pathways between HHLA2 and its two receptors on T cells and NK cells remain controversial. Aim of Review: Here, we reviewed recent studies about HHLA2 ligand interactions with KIR3DL3 and TMIGD2. We focused on elucidating the pathways between KIR3DL3/TMIGD2 and HHLA2 as well as their function in tumour progression. We also addressed the relationship between HHLA2 expression and the clinical prognosis of cancer patients. Key Scientific Concepts of Review: KIR3DL3/TMIGD2-HHLA2 may represent novel pathways within the tumour microenvironment and serve as crucial immune checkpoints for developing novel therapeutic drugs against human cancer.http://www.sciencedirect.com/science/article/pii/S2090123222001679HHLA2KIR3DL3TMIGD2PathwayCancerImmunotherapy |
| spellingShingle | Yang Li Chao Lv Yang Yu Baokang Wu Yizhou Zhang Qi Lang Zhiyun Liang Chongli Zhong Yu Shi Shukun Han Feng Xu Yu Tian KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy Journal of Advanced Research HHLA2 KIR3DL3 TMIGD2 Pathway Cancer Immunotherapy |
| title | KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| title_full | KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| title_fullStr | KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| title_full_unstemmed | KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| title_short | KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| title_sort | kir3dl3 hhla2 and tmigd2 hhla2 pathways the dual role of hhla2 in immune responses and its potential therapeutic approach for cancer immunotherapy |
| topic | HHLA2 KIR3DL3 TMIGD2 Pathway Cancer Immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2090123222001679 |
| work_keys_str_mv | AT yangli kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT chaolv kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT yangyu kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT baokangwu kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT yizhouzhang kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT qilang kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT zhiyunliang kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT chonglizhong kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT yushi kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT shukunhan kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT fengxu kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy AT yutian kir3dl3hhla2andtmigd2hhla2pathwaysthedualroleofhhla2inimmuneresponsesanditspotentialtherapeuticapproachforcancerimmunotherapy |